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1.  INTRODUCTION 
 
Solubility phenomena (i.e. dissolution and precipitation reactions) are the 
physicochemical basis of numerous biological processes. These include, for 
instance: 
 
•  gas solubilities in respiratory and photosynthetic processes; the solu- 
bility of volatile anaesthetics; 
• the crystallisation, both in biologically controlled and pathological 
processes, of biogenic minerals in a variety of body fluids; the resorp- 
tion of mineralised tissue; 
•  the accumulation, due to their higher solubility, of lipophilic substances, 
such as pesticides, in liquid fat contained, e.g. in adipose tissue or 
human milk; 
• the incorporation of metal ions such as strontium (including the 
radioactive 90Sr isotope) in bone, by co-precipitation and solid-solution 
formation. Since Sr stabilises bone apatite crystals (i.e. decreases sol- 
ubility), it may retard the resorption of the calcified matrix and thus 
have therapeutic potential in the prevention and treatment of 
osteopenic disorders [1]. In dental enamel, a combination of strontium 
and  fluoride  was  reported  to  be  more  effective  in  stabilising  the 
apatetic structure than each element alone [2]. This results in an 
improved crystal resistance to degradation by bacterial acids and hence 
may be useful for the prevention of dental caries [3]. 
 
All of these solubility phenomena are governed by the laws of thermo- 
dynamics and kinetics. The human body is essentially an isothermal system 
(a notable exception, related to gout, has been reported in the literature – see tions are high in potassium, magnesium and phosphate ions and low in 
 
 
 
below). Thus, the pertinent in vitro measurements have almost always been 
performed at 37°C. However, reactions in body fluids are complicated by the 
presence of organic complexing agents which affect the speciation of metal 
ions (i.e. their distribution among these complexes). Computer speciation 
modelling of biofluids, which has a long history [4], has also to be considered 
in the modelling of solubility equilibria. The presence of organic macromol- 
ecules such as proteins provides templates or matrices which control the crys- 
tallisation of biogenic minerals and modify their morphologies. The mineral 
phase in organic/inorganic composites (such as teeth or bone) may form 
nanosized crystals, which exhibit unusual dissolution and crystallisation 
behaviour [5]. A new biomineralisation mechanism invoking liquid precursors 
and their importance for normal and pathological biomineralisation processes 
has been proposed [6]. These and other aspects of normal and pathological 
biomineralisation processes have been reviewed recently [7]. 
 
 
2.  BODY FLUIDS 
 
The human body contains 60% water, which is an excellent solvent for 
electrolytes and plasma proteins [8]. Because all cell membranes are freely 
permeable to water, intra- and extracellular fluids are generally considered 
to be in osmotic equilibrium. Therefore, the osmolality  (the total molality 
of individual ionic and neutral solute species that contribute to the osmotic 
pressure) of the extracellular fluid is approximately equal to that of the 
intracellular fluid (ICF) and hence plasma osmolality is a guide to intracellu- 
lar osmolality. Normal osmolality in plasma is ~0.30 ‘osmoles’ (kg water)-1. 
This is contributed mainly by sodium, chloride, potassium, urea and glu- 
cose, and additionally by other ions and substances in the blood. Most of the 
body fluids are isotonic (“of equal osmotic pressure”, when only imperme- 
ant solutes are taken into account), with the notable exceptions of urine, 
sweat and saliva [9]. 
Forty-two litres of solutions involved in the major body fluids of a 
70 kg human are distributed as follows [8]: 
 
1.   Intracellular fluid (ICF, 28 l) is the sum of all the solutions inside the 
ca. 1014  cells of the body. Although each of them contains a separate 
individual solution and different cell types are chemically different, 
their internal solutions all share a few common features that distin- 
guish them from extracellular fluids. For instance, intracellular solu-  
 
 
sodium and chloride, and contain high concentrations of organic acids 
and proteins. These bind metal ions efficiently so that crystallisation of 
solids does not normally occur in ICF. 
2.  Extracellular fluids have various functions that are beneficial to the 
organism [9]. These include heat homeostasis (through blood and 
sweat), transport functions (energy sources, nutrients, electrolytes, dis- 
solved gases, hormones, excretory products, etc.), wetting (saliva), 
lubrication (tears, synovial fluid) and neutralisation (saliva, biliary and 
pancreatic juices), among others [9]. Various extracellular fluids are 
prone to pathological calcification and stone formation. They are com- 
monly subdivided as follows: 
a.  Interstitial fluid (ISF, 10.5 l) is the sum of all the thin layers of tis- 
sue fluid in the interstices between cells throughout the body and 
constitutes the internal environment whose stable composition is 
essential for homeostasis. Its major chemical features are low potas- 
sium and magnesium ion concentrations, high sodium, chloride and 
bicarbonate concentrations, and very low or negligible concentra- 
tions of proteins or other organic acids. A special subset of ISF is 
the lymphatic fluid, or lymph, which plays a part in the transport of 
tissue fluid until it rejoins the blood. Since tissue fluid passes into 
the surrounding lymph vessels and lymph can thus be sampled and 
analysed, measurements of lymph composition are often cited as 
approximations of the composition of ISF. 
b.  Blood plasma (3 l) is the ISF of a very special (liquid) tissue, namely 
whole blood. It circulates rapidly throughout the body and is in 
effective diffusion equilibrium with the ISF for most solutes except 
macromolecules. Plasma therefore differs in composition from ISF 
mainly in its protein content. 
c.  Other fluids amount to 0.5  l. This category includes a variety of 
small volumes of special, usually rather small and localised, solu- 
tions such as aqueous humour (the clear, watery fluid in the eye that 
fills the space between the back surface of the cornea and the front 
surface of the vitreous humour [10]), synovial fluid (in joints), bile, 
saliva and many others. These are sometimes referred to as ‘trans- 
cellular’ fluids. Two of these special fluids have extreme pH values: 
gastric and pancreatic secretion. Gastric acid can be as concentrated 
as 0.15  mol  kg-1   HCl,  and  the  alkaline  pancreatic  juice  contains 
high concentrations   of sodium, calcium and hydrogen carbonate, 
but almost no chloride. in  classical  and  modern  textbooks,  e.g.  [16–18],  and  reviews,  e.g.  [6]. 
 
 
 
3.  SOLUBILITY PHENOMENA IN BODY FLUIDS 
 
3.1.  Gas Solubilities 
Except for blood plasma passing the pulmonary capillaries, body fluids 
are not even in contact with, let alone at equilibrium with, a gas phase. They 
nonetheless contain dissolved gases, especially CO2, whose concentration is 
an important determinant of pH and therefore of acid–base behaviour in all 
body fluids [11]. Attempts to correlate and predict the solubilities of non- 
electrolytes, particularly gases and volatile anaesthetics [12], in biological 
tissues and fluids are more complicated compared to pure solvents, since 
biological systems are heterogeneous and cases of specific binding of solute 
molecules are common. In these situations, Henry’s law is no longer obeyed. 
For instance, oxygen solubility in blood plasma is ca. 5 ml l-1  at 37°C but 
considerably higher (ca. 200  ml  l-1) in whole blood due to the binding of 
oxygen to haemoglobin, which follows a well-known sigmoid binding curve 
resulting from the cooperative action of the haemoglobin alpha and beta 
chains. The effect of haematocrit (the fraction of blood composed of red blood 
cells) on the solubility of several volatile anaesthetics in blood is much less 
pronounced but significant (10–20%) [13]. 
Abraham et al. [14] have reported solubility correlations for a wide 
variety of systems that follow Henry’s law. Gas/liquid partition coefficients 
for biofluids are modelled by a suitable combination of gas/water and gas/oil 
partition coefficients, thus allowing for the hydrophobicity of a given bio- 
logical tissue or fluid. This method is furthermore able to provide a measure 
for the tissue/blood distribution of non-electrolytes (which may also be esti- 
mated using octanol–water partition coefficients [15]). 
 
3.2.  Normal Biogenic Mineralisation 
Biomineralisation commonly refers to the complex biological process 
by which living organisms synthesise the inorganic materials of their hard 
tissues. Normal (as opposed to pathological) biomineralisation is frequently 
characterised by a high degree of specificity and control, which is exerted dur- 
ing the interaction between the mineral and the organic constituents on dif- 
ferent hierarchical levels and directs the nucleation, growth and morphology 
of ‘normal’ biomaterials such as bone and teeth. The structure and mechanism 
of formation of these organic/mineral biocomposites, as well as the amazing 
diversity and beauty of the very elaborate and complex crystal morpholo- 
gies produced by various organisms, have been comprehensively described  
 
 
The authors of the latter review present a somewhat different perspective on 
biomineralisation, with emphasis on the role of amorphous precursor phases, 
which may be relevant to biologically controlled mineralisation in bones and 
teeth (and also to pathological mineralisation such as in kidney stones) [6]. 
The solubilities of the various calcium phosphates found in mineralised 
tissues at different states of maturation have been systematically reviewed [19]. 
Besides its skeletal support function, bone also provides an important meta- 
bolic function in the regulation of the ionic composition of the body fluids, 
serving as a reservoir for cationic and anionic species by resorption and depo- 
sition of this mineralised tissue [20]. The mineral phase in bones and teeth 
consists of apatite nanocrystals, which are not only crucial for the superior 
mechanical properties of these biocomposites, but also exhibit some unusual 
solubility behaviour. While these nanocrystals are usually considered to be 
stabilised by their intimate association with the organic matrix and thus 
become unstable once the collagen is removed (such as by osteoclastic secre- 
tion  of enzymes  enabling  the  biological  resorption  of bone)  [6],  studies 
of their dissolution kinetics have shown that they can become dynamically 
stabilised (i.e. they do not dissolve any further) even at considerable under- 
saturation. These and other aspects of peculiar solubility phenomena con- 
cerning nanosized biominerals have been discussed recently [5]. 
 
3.3.  Pathogenic ‘Calcifications’ 
Pathological intra- and extracellular calcifications are frequently initiated 
at the biologic membranes of mitochondria or matrix vesicles, respectively, 
through the interaction of phosphatase enzymes with calcium-binding phos- 
pholipids, both of which are membrane-bound [21]. Sequestration of calcium 
by mitochondria is a common biochemical mechanism mediating various 
forms of toxic cell death. Pathological cellular calcification may therefore be 
characterised by mineral-laden mitochondria, as described for a case of hepa- 
tocellular calcification [22]. Cellular microcalcification has also been observed 
in a diversity of human pathologies, such as vascular dementia, Alzheimer’s 
disease, Parkinson’s disease, astrogliomas and post-traumatic epilepsy. Rodent 
models of central nervous system neurodegeneration indicate that this is due 
to the inability of neurons to regulate intracellular calcium levels properly 
[23]. Hydroxyapatite crystals are formed first within the protective micro- 
environment of the membrane-enclosed microspace, aggregate progressively 
throughout the cell and at exposure to the Ca2+-rich extracellular fluid, for 
instance, after cell death, they can serve as nuclei or templates supporting 
progressive, autocatalytic mineral crystal proliferation [21]. The nucleoside  
 
 
triphosphates have been found to have a significant inhibiting effect on the 
hydroxyapatite crystal growth process and thus may play a beneficial role 
in regulating intracellular calcification [24]. 
In dystrophic calcifications, the mineralisation occurs without a sys- 
temic mineral imbalance as a response to previous cell injury on the micro- 
scopic level or any soft tissue damage, including that involved in implantation 
of medical devices or bioprosthetic heart valves [25]. Injury and cell death 
can cause the release of intracellular phosphate ions and fatty acids into the 
extracellular environment, where sparingly soluble calcium salts are precipi- 
tated in tissues. This type of calcification is particularly common in athero- 
sclerosis and diseases associated with chronic inflammation. 
Pathological intracellular calcifications can also occur in conditions 
associated with hypercalcaemia [26] – excess levels of calcium in the blood, 
caused, e.g. by hyperparathyroidism (excess secretion of parathyroid hormone 
by overactive parathyroid glands which normally regulate calcium levels 
tightly) or malignancy [27]. Intramitochondrial calcifications often precede 
necrosis, and fusion or rupture of calcified mitochondria results in calcareous 
masses in the cytoplasm or outside of the cell. Much progress has been made 
in the ultramicroscopic identification and systematic classification of these 
calcifications [28]. 
Since extracellular body fluids exhibit high calcium concentrations, 
many of them are supersaturated with respect to calcium compounds, even 
in the healthy organism. Examples of supersaturated body fluids are urine 
(oxalates, phosphates), blood plasma and saliva (phosphates), pancreatic 
secretions and bile (carbonates). Body fluids may also become supersatu- 
rated with respect to intermediate or final metabolic products, e.g. urine (uric 
acid, xanthine, cystine), bile and blood plasma (cholesterol), and synovial 
fluid (sodium hydrogenurate monohydrate). Despite considerable research 
effort, it is presently not clear why pathological mineralisation does not occur 
indiscriminately in the supersaturated body fluids occurring in all humans. 
It seems that (i) the presence of heterogeneous nucleants and (ii) a deficit of 
crystallisation inhibitors play a crucial role in pathological situations [29]. For 
instance, magnesium has found to be an important inhibitor of many patho- 
logical calcifications [30]. Macromolecules can interact with crystals both as 
inhibitors and as promoters of crystallisation and the relationship between 
pathological and benign mineralisation is not fully understood as yet [31]. 
A paramount example is the multifaceted role of the glycoprotein osteopontin 
in bone remodelling, urolithiasis, atherosclerosis, inflammatory and immune 
response, and cancer progression    [32]. A somewhat controversial    debate  
 
 
concerns the role of putative nanobacteria in various forms of calcification 
(see the discussion in Ref. 5). 
 
3.3.1.  Renal Calculi 
Approximately 10% of the human population (with regional differences 
indicating both genetic and environmental factors [33]) is affected by the 
formation of stones or calculi in the urinary tract. Urolithiasis is not only a 
painful condition, but also causes annual costs to the health system in the 
order of billions of dollars in the USA alone [34, 35]. Based on their com- 
position, structure and location in the urinary tract, renal stones have been 
classified into 11 groups and their formation mechanisms have been discussed 
together with alterations in urinary parameters and metabolic risk factors for 
renal lithiasis [35]. Approximately 70% of these stones contain calcium 
oxalate  monohydrate  (COM)  and  dihydrate  as major  components,  while 
other calculi are composed of ammonium magnesium phosphate (struvite), 
calcium phosphates (hydroxyapatite and brushite), uric acid and urates, cystine 
and xanthine. An accurate knowledge of the solubilities of these substances 
is necessary to understand the cause of renal or bladder calculi formation 
and find ways towards its prevention and treatment [36]. 
Due to its vital functions related to water balance and the excretion of 
metabolic end products, the composition and pH of urine can vary widely 
(which is in contrast to the homeostatic internal environment provided by 
most other body fluids). Although the solubilities of uric acid (the end product 
of purine metabolism in humans), xanthine (an intermediate product of purine 
metabolism) and L-cystine (the least soluble amino acid) strongly depend on 
pH, accurate measurements performed by our group (Fig. 1) have shown that 
they hardly depend on the nature and concentration of urinary constituents 
[36–41], including organic urine components such as urea and creatinine [38]. 
The solubility of cystine in real urine was found to be comparable to that in 
synthetic solutions [39]. For xanthine [40] and uric acid [42], thermodynamic 
consistency of solubility and calorimetric data has been demonstrated. 
Calcium oxalate and phosphate solubilities, on the other hand, strongly 
depend on the concentration of ions that form complexes with calcium, phos- 
phate or oxalate, particularly citrate or magnesium ions [43–45]. Due to the 
protonation of these anions, the concentration of these complexes depends on 
pH, which contributes to the pH dependence of solubility. Whereas the solu- 
bility of calcium oxalate is only slightly pH dependant in the urinary pH 
range [45], the solubility of phosphates decreases with pH [43, 44]. We have 
developed  a  urine  model  [43–45]  based  on  the  JESS  Expert  Speciation  
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Fig. 1. Solubilities S of stone-forming substances in urine-like liquors at 37°C. (Cys) 
L-Cystine in standard-reference artificial urine (dots), real urine (circles) and 0.30 mol kg-1 
NaCl (triangles) [39]. (COM) Calcium oxalate monohydrate (as [Ca2+]tot) in standard- 
reference artificial urine (dots) [45]. (UAA) Anhydrous uric acid in standard-reference 
artificial urine (diamonds) and 0.30 mol kg-1 NaCl + 0.30 mol kg-1 urea (squares) [37, 38]. 
(Xan) Xanthine in 0.30 mol kg-1 NaCl (squares) [40]. The experimental data are compared 
to model calculations (lines) described in the respective publications. 
 
 
System [46–49] that permits reliable solubility calculations by taking all of 
these complexes into account. This and other urine models and their appli- 
cations have been reviewed recently [5]. 
Due to deprotonation reactions occurring at higher pH, the solubilities 
of uric acid, xanthine and cystine increase with pH. For cystine and particularly 
for uric acid stones, therapies based on the administration of substances that 
increase the urinary pH have been successfully applied. However, the solu- 
bility increase of xanthine at high pH is of little therapeutical use, as is that 
of cystine at low pH (caused by the protonation of the amino groups). Both 
of these pH ranges are outside the normal urinary pH range and attempts to 
access them by medication may cause the precipitation of uric acid and 
phosphates at low and high pH, respectively. It should be noted that the solu- 
bility of the metastable uric acid dihydrate, which is also found in kidney 
stones and is regarded as the kinetically favoured precipitation product, is 
twice as high as that of anhydrous uric acid [37]. 
The solubility of COM in artificial urine is almost pH independent 
(at low pH the solubility increases because of the protonation of the oxalate  
 
 
ion and at high pH it increases slightly because of the deprotonation of cit- 
rate which then complexes Ca2+). The solubility of calcium oxalate dihy- 
drate, which is also found in kidney stones and whose precipitation in complex 
solutions is often kinetically controlled, in artificial urine is three times 
higher than that of the monohydrate [45]. 
Renal lithiasis is a multifactorial disease, with numerous factors con- 
tributing to the actual stone formation [6, 33, 35]. Although various condi- 
tions promote, or fail to inhibit, the crystallisation of stone-forming substances, 
supersaturation is an indispensable factor. Solubility modelling can there- 
fore give crucial information on the risk of pathological mineralisation in 
general and renal lithiasis in particular. A variety of computer codes have 
been applied to assess the effects of diet, fluid intake and medication [5], and 
an application of a JESS speciation model similar to ours [43–45] has been 
reported [50]. 
 
3.3.2.  Atherosclerosis 
Cardiovascular disease due to atherosclerosis is the major cause of 
mortality and morbidity in industrialised countries. Atherosclerosis is char- 
acterised by hardening (and loss of elasticity) of medium or large arteries, 
eventually leading to narrowing of the vessel lumen. Initial steps are an 
immune reaction to cell damage caused by oxidation of low-density lipopro- 
tein (LDL) in the blood vessel lining (endothelium), which involves redox- 
active copper and iron ions [51]. The resulting inflammation response leads 
to deposition of atheromatous plaques in the inner wall of the arteries 
(intima), followed by intracellular microcalcifications within vascular smooth 
muscle cells of the muscular layer surrounding the plaques. As cells die, 
extracellular calcium salt deposits are formed between the muscular wall and 
the outer portion of the atheromatous plaques [52]. The main components of 
human atherosclerotic lesions are calcium salts, particularly apatites, and cho- 
lesterol crystals [53, 54], which accumulate predominantly within the central 
core region of the lesions and probably nucleate the deposition of apatite [55]. 
 
3.3.3.  Crystal Arthritis: Gout and Pseudogout 
The very painful inflammations associated with gouty arthritis are 
induced by the deposition of needle-shaped sodium hydrogenurate mono- 
hydrate crystals in synovial fluids around joints [56]. The solubility of 
sodium hydrogenurate monohydrate is strongly pH dependant and is lowest 
at physiological pH [37]. It has been observed that only a small percentage 
of individuals with hyperuricaemic body fluids (which are supersaturated  
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with respect to sodium hydrogenurate monohydrate) have ever had a gouty 
attack. Indeed, normal synovial fluids, serum albumin and heparin have been 
found to inhibit sodium hydrogenurate monohydrate crystallisation, whereas 
synovial fluids of gouty patients have nucleated this substance [57]. It has 
also been established in our solubility study [37] that even in 0.15 mol kg-1 
NaCl at higher pH, saturated uric acid solutions can become highly super- 
saturated with respect to sodium hydrogenurate monohydrate without any 
crystallisation occurring. The solubility of sodium hydrogenurate mono- 
hydrate is markedly temperature dependant (Fig. 2) [37] and it has been 
speculated that the preferred occurrence of gouty attacks in the joints of the 
extremities is due to the lower temperature of these parts of the body [58]. 
Pseudogout refers to the clinical syndrome associated with the deposi- 
tion of calcium diphosphate dihydrate crystals in the hyaline articular carti- 
lage or fibrocartilage. The shedding of crystals in the joint space after rupture 
of a calcium diphosphate dihydrate deposit produces an acute inflammatory 
synovitis, which resembles a classic gouty attack and is thus often misdiag- 
nosed as gout. Calcium diphosphate dihydrate crystal deposition is often the 
result of an underlying disease (such as haemochromatosis or hyper- 
parathyroidism) and cannot be reversed. These and other aspects of pseudo- 
gout and the solubilities of the substances involved have been reviewed 
recently [19]. 
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Fig.  2.  Solubility  of  sodium  hydrogenurate  monohydrate  in  0.15 mol kg-1   NaCl  at 
physiological pH at 25, 32, 37 and 42°C [37].  
 
 
3.3.4.  Gallstones 
More than 80% of gallstones in the Western world are cholesterol gall- 
stones [59]. Other gallstones contain bilirubin as their main constituent, but 
inorganic or organic calcium salts (carbonate, phosphate, bilirubinate, palmi- 
tate) are almost always present [19]. 
Crystallisation of biliary cholesterol monohydrate is a multiphase 
process not yet fully understood [60]. Bile is normally supersaturated with 
respect to cholesterol [61] which is solubilised by bile salts (the soluble end 
product of cholesterol metabolism, such as sodium glycocholate and sodium 
taurocholate [9]) within micelles, whose solubilising capacity is considerably 
increased by the incorporation of phospholipid molecules such as lecithin 
[62]. Biliary vesicles contain virtually no bile salts but may accumulate cho- 
lesterol up to a cholesterol/phospholipid ratio of 2:1 (by phospholipid transfer 
to micelles) [63]. These thermodynamically unstable (but kinetically stabilised) 
vesicles then aggregate and nucleate cholesterol crystals [64, 65]. The mecha- 
nism of this crucial micelle-to-vesicle transition has been the subject of various 
physicochemical studies, including, e.g. calorimetric, turbidimetric, dynamic 
light and neutron scattering methods [66–69]. 
The solubility of cholesterol has been studied as a function of several 
physiologically important variables, such as the concentrations of various 
bile salts and phospholipids, e.g. [70, 71]. Carey [72] has generated exten- 
sive cholesterol solubility tables for native bile by identifying two key 
physicochemical variables, the bile salt-to-lecithin ratio and the total lipid 
concentration (bile salts + lecithin + cholesterol), that determine the solu- 
bility of cholesterol in bile [70]. These tables permit calculation of the litho- 
genic index or percent cholesterol saturation of native bile. 
 
3.3.5.  Pancreatic Stones 
Calcium carbonate is a major constituent of pancreatic stones 
(consisting of ca. 95% calcite) and is found occasionally in salivary stones 
and many pigment gallstones, since these three gastrointestinal secretions 
have high pH values and contain high hydrogen carbonate concentrations. 
The normal function of pancreatic secretion is to contribute to the neu- 
tralisation of gastric acid and support digestion by a variety of enzymes. 
A physicochemical model of calcite solubility in pancreatic juice has been 
developed that takes the complexation constants of calcium ions with 
(hydrogen-) carbonate and proteins into account [73]. All of these ligands 
are important buffers for calcium ions in the juice [73] and various in vitro 
studies have been performed to investigate the dissolution of stones as well  
 
 
as the influence of additives on calcium carbonate saturation in pancreatic 
secretions (see Ref. 5). 
 
3.3.6.  Salivary and Dental Calculi 
Williams et al. [74] have developed a thermodynamic model of saliva 
which is able to simulate the distribution and speciation of metal ions in this 
biological fluid. The model predicts that in the pH range of 5–6, saliva becomes 
supersaturated with respect to calcium phosphates in the order octacalcium 
phosphate < hydroxyapatite < fluoroapatite. This indicates that under nor- 
mal conditions, no demineralisation of teeth should occur. However, dietary 
acids are detrimental and are thus normally neutralised by increased secretion 
of saliva. 
Therefore, a thermodynamic driving force also exists for the formation 
of pathological calcifications that obstruct the salivary glands. These sali- 
vary calculi or sialoliths usually contain organic matter and various calcium 
phosphates [19], particularly carbonateapatites and hydroxyapatite. The lat- 
ter exhibit macro- and microstructures that are practically identical to those 
found in hydroxyapatite renal calculi [35]. It has also been reported that the 
saliva of stone formers, when compared to that of healthy subjects, was 
characterised by a higher calcium phosphate supersaturation and deficit of 
crystallisation inhibitors (magnesium, phytate). These factors thus favoured 
crystallisation, particularly when combined with morphoanatomic disorders 
(stenosis, diverticuli) within the salivary duct [35]. 
Dental calculi, i.e. calcifications of the dental plaque biofilm, contain 
various calcium phosphates, since these inorganic ions are provided by saliva 
or crevicular fluids. Although the pattern of calcification of oral micro- 
organisms, either intra- or extracellularly, is mainly a characteristic of each 
bacterial species or strain [75], it may be influenced by nutritional factors, such 
as saliva proteins, as well [76]. The interactions of saliva with dental calculi 
and its role in preventing dental caries by controlling the enamel de- and 
remineralisation processes have been reviewed [19]. 
 
3.4.  Solubility of Other Metal Compounds 
The deposition of other sparingly soluble metal compounds is usually 
associated with disturbances in homeostasis, i.e. the delicate regulation of 
metal ion concentrations in body fluids, due to various forms of disease. If 
these disorders result in metal overload of body fluids, solids may deposit 
in various tissues and damage them. In humans, metal overload diseases 
concern  primarily  iron  and  copper  ions,  which  are  moreover  intimately  
 
 
involved in free radical reactions associated with, e.g. atherosclerosis and 
central nervous system diseases [77]. The toxicity due to oxidative cell dam- 
age of iron oxyhydroxide deposits has been related to their solubilities [78]. 
Iron overload in humans can be non-anaemic (primary haemochro- 
matosis) or anaemic (thalassemia). While non-anaemic iron overload is effec- 
tively treated by phlebotomy (bloodletting), a chelating agent is necessary 
to increase iron excretion in the case of thalassemia [79]. Without treatment, 
excess iron deposits as haemosiderin, which may contain iron(III) oxyhy- 
droxides that are either amorphous or based on ferrihydrite or goethite struc- 
tures [78]. Recent progress on the (Mössbauer) spectroscopic characterisation 
of these deposits and their reactivity with chelating agents has been reviewed 
[78]. Copper overload in humans is mainly caused by Wilson’s disease and has 
to be treated by life-long chelation therapy, cf. [5]. 
Other metals, which may precipitate in body fluids or affect the solu- 
bilities of other biominerals, are sometimes ingested with food or medications. 
A prominent example is aluminium, which is contained in food and various 
antacids in variable amounts. Although acute aluminium intoxications are very 
rare, subacute and chronic forms of aluminium intoxications due to oral intake 
have been debated [80]. In particular, a combination of aluminium-containing 
medications with (complexing) citrate or tartrate solutions (often admini- 
stered to uraemic patients or contained in soft drinks, respectively) can sub- 
stantially elevate the absorption of aluminium [81] and has been repeatedly 
associated with the onset of neurological illness [80]. The evidence impli- 
cating aluminium with Alzheimer’s disease is controversial [82]. Aluminium 
hydroxide has a very low solubility at physiological (and intestinal) pH, but 
the metal rather complexes with phosphate in the intestine, resulting in excess 
phosphate excretion, inhibition of phosphate adsorption and reduced urinary 
and serum phosphate levels. This phosphorous depletion syndrome induces 
adverse effects on calcium metabolism and may cause severe calcium loss 
which eventually leads to the development of osteoporosis or osteomalacia 
[83]. Aluminium also forms complexes with intestinal fluoride, an element 
important for the normal bone structure [83]. 
 
4.  CONCLUSION 
 
With the exception of urine whose composition can vary over wide ranges, 
physiological solutions are usually not highly supersaturated with respect to 
biominerals. A careful control of ion balance, which must be maintained for 
physiological function, including avoidance of undesirable precipitates, can  
 
 
then be accomplished by biologically controlled resorption and deposition 
of mineralised tissue. Homeostatic regulation of ion concentration is true of 
all biological systems, and most likely lies at the evolutionary foundation of 
regulating biomineral deposition [6]. 
Considerable research has been devoted to the study of solubility pheno- 
mena in body fluids, particularly in the field of pathological mineralisation, 
aiming at its prevention and treatment. Although the underlying mechanisms 
and interactions with low-molecular-weight  ligands and biological macro- 
molecules are inherently complex, computerised modelling of solubility equi- 
libria in body fluids has proven a valuable tool for predicting supersaturation 
and hence the risk of undesirable precipitation. 
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